author-photo

Kevin S. Currie

39

Papers

868

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Discovery of Lanraplenib (GS-9876), a Once Daily Spleen Tyrosine Kinase Inhibitor for the Treatment of Autoimmune Diseases

2020 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (0)
Small-Molecule Agents for the Treatment of Inflammatory Bowel Disease

2019 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (7)
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation

2019 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (5)
COMPOSÉS MODULANT LE FXR (NR1H4)

2017
Show All
- Source
- Cite
- Save
Citations (0)
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell–associated damage in IFNα-driven lupus nephritis

2017 JCI insight
Show All
- Source
- Cite
- Save
Citations (49)
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.

2016 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (28)
FRI0049 Preclinical Characterization of GS-9876, A Novel, Oral SYK Inhibitor That Shows Efficacy in Multiple Established Rat Models of Collagen-Induced Arthritis

2016 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (1)
Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834.

2015 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (44)
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

2014 Oncotarget
Show All
- Source
- Cite
- Save
Citations (54)